View in EDS HTML Full Text PDF Full Text

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Saved in:
Bibliographic Details
Title: Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
Authors: Jansen MP; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands. Electronic address: m.p.h.m.jansen@erasmusmc.nl., Sas L; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium; Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, B2650 Antwerp, Belgium., Sieuwerts AM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., Van Cauwenberghe C; Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium., Ramirez-Ardila D; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., Look M; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., Ruigrok-Ritstier K; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., Finetti P; Marseille Cancer Research Center (CRCM), UMR891 Inserm, Institut Paoli-Calmettes (IPC), Department of Molecular Oncology, Marseille, France., Bertucci F; Marseille Cancer Research Center (CRCM), UMR891 Inserm, Institut Paoli-Calmettes (IPC), Department of Molecular Oncology, Marseille, France., Timmermans MM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., van Deurzen CH; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., Martens JW; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., Simon I; Research and Development, Agendia BV, Amsterdam, The Netherlands., Roepman P; Research and Development, Agendia BV, Amsterdam, The Netherlands., Linn SC; The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dam P; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium., Kok M; The Netherlands Cancer Institute, Amsterdam, The Netherlands., Lardon F; Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, B2650 Antwerp, Belgium., Vermeulen PB; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium., Foekens JA; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., Dirix L; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium., Berns EM; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands., Van Laere S; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium.
Source: Molecular oncology [Mol Oncol] 2015 Jun; Vol. 9 (6), pp. 1218-33. Date of Electronic Publication: 2015 Mar 04.
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 25771305
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jansen+MP%22">Jansen MP</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands. Electronic address: m.p.h.m.jansen@erasmusmc.nl.<br /><searchLink fieldCode="AU" term="%22Sas+L%22">Sas L</searchLink>; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium; Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, B2650 Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Sieuwerts+AM%22">Sieuwerts AM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Van+Cauwenberghe+C%22">Van Cauwenberghe C</searchLink>; Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Ramirez-Ardila+D%22">Ramirez-Ardila D</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Look+M%22">Look M</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Ruigrok-Ritstier+K%22">Ruigrok-Ritstier K</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Finetti+P%22">Finetti P</searchLink>; Marseille Cancer Research Center (CRCM), UMR891 Inserm, Institut Paoli-Calmettes (IPC), Department of Molecular Oncology, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Bertucci+F%22">Bertucci F</searchLink>; Marseille Cancer Research Center (CRCM), UMR891 Inserm, Institut Paoli-Calmettes (IPC), Department of Molecular Oncology, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Timmermans+MM%22">Timmermans MM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Deurzen+CH%22">van Deurzen CH</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Martens+JW%22">Martens JW</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Simon+I%22">Simon I</searchLink>; Research and Development, Agendia BV, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Roepman+P%22">Roepman P</searchLink>; Research and Development, Agendia BV, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Linn+SC%22">Linn SC</searchLink>; The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Dam+P%22">van Dam P</searchLink>; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium.<br /><searchLink fieldCode="AU" term="%22Kok+M%22">Kok M</searchLink>; The Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Lardon+F%22">Lardon F</searchLink>; Department of Medical Oncology, University Hospital Antwerp, Wilrijkstraat 10, B2650 Antwerp, Belgium.<br /><searchLink fieldCode="AU" term="%22Vermeulen+PB%22">Vermeulen PB</searchLink>; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium.<br /><searchLink fieldCode="AU" term="%22Foekens+JA%22">Foekens JA</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Dirix+L%22">Dirix L</searchLink>; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium.<br /><searchLink fieldCode="AU" term="%22Berns+EM%22">Berns EM</searchLink>; Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Wytemaweg 80, 3000 CA Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Van+Laere+S%22">Van Laere S</searchLink>; Translational Cancer Research Unit, GZA Hospitals St-Augustinus, Oosterveldlaan 24, Antwerp B2610, Belgium; Department of Oncology, KU Leuven, Leuven, Belgium.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101308230%22">Molecular oncology</searchLink> [Mol Oncol] 2015 Jun; Vol. 9 (6), pp. 1218-33. <i>Date of Electronic Publication: </i>2015 Mar 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22John+Wiley+%26+Sons%2C+Inc%22">John Wiley & Sons, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101308230 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1878-0261 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215747891%22">15747891 </searchLink><i>NLM ISO Abbreviation: </i>Mol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=25771305
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.molonc.2015.02.006
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1218
    Titles:
      – TitleFull: Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jansen MP
      – PersonEntity:
          Name:
            NameFull: Sas L
      – PersonEntity:
          Name:
            NameFull: Sieuwerts AM
      – PersonEntity:
          Name:
            NameFull: Van Cauwenberghe C
      – PersonEntity:
          Name:
            NameFull: Ramirez-Ardila D
      – PersonEntity:
          Name:
            NameFull: Look M
      – PersonEntity:
          Name:
            NameFull: Ruigrok-Ritstier K
      – PersonEntity:
          Name:
            NameFull: Finetti P
      – PersonEntity:
          Name:
            NameFull: Bertucci F
      – PersonEntity:
          Name:
            NameFull: Timmermans MM
      – PersonEntity:
          Name:
            NameFull: van Deurzen CH
      – PersonEntity:
          Name:
            NameFull: Martens JW
      – PersonEntity:
          Name:
            NameFull: Simon I
      – PersonEntity:
          Name:
            NameFull: Roepman P
      – PersonEntity:
          Name:
            NameFull: Linn SC
      – PersonEntity:
          Name:
            NameFull: van Dam P
      – PersonEntity:
          Name:
            NameFull: Kok M
      – PersonEntity:
          Name:
            NameFull: Lardon F
      – PersonEntity:
          Name:
            NameFull: Vermeulen PB
      – PersonEntity:
          Name:
            NameFull: Foekens JA
      – PersonEntity:
          Name:
            NameFull: Dirix L
      – PersonEntity:
          Name:
            NameFull: Berns EM
      – PersonEntity:
          Name:
            NameFull: Van Laere S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2015 Jun
              Type: published
              Y: 2015
          Identifiers:
            – Type: issn-electronic
              Value: 1878-0261
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Molecular oncology
              Type: main
ResultId 1